In multiple experiments, C-a16 lipids, which contain a phenol group, outperformed LNPs used in currently available mRNA ...

GenesisM’s enhanced core platform is designed to provide long-term operational flexibility and accelerate buildout timeline.

David Baker’s lab has successfully designed binders to disordered proteins, expanding therapeutic access to over 50% of the human proteome.